【石药集团:注射用西罗莫司(白蛋白结合型)获突破性治疗认定】石药集团公告,集团开发的注射用西罗莫司(白蛋白结合型)获国家药品监督管理局授予突破性治疗认定,拟定适应症为单药用于恶性血管周围上皮样细胞瘤。该产品采用特殊技术将西罗莫司包裹于人血白蛋白中,克服口服制剂无法向靶部位递送足够浓度药量的缺点,实现了西罗莫司的注射给药,且无需激素预处理。同时,该产品拓展了西罗莫司的应用领域,有望实现治疗mTOR信号通路驱动的一系列疾病。

金融界
28 Feb
石药集团公告,集团开发的注射用西罗莫司(白蛋白结合型)获国家药品监督管理局授予突破性治疗认定,拟定适应症为单药用于恶性血管周围上皮样细胞瘤。该产品采用特殊技术将西罗莫司包裹于人血白蛋白中,克服口服制剂无法向靶部位递送足够浓度药量的缺点,实现了西罗莫司的注射给药,且无需激素预处理。同时,该产品拓展了西罗莫司的应用领域,有望实现治疗mTOR信号通路驱动的一系列疾病。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10